Damjanov Nevena, Meropol Neal J
Temple University, Fox Chase-Temple Cancer Center, Philadelphia, Pennsylvania 19140, USA.
Oncology (Williston Park). 2004 Apr;18(4):479-88; discussion 488, 493, 497 passim.
The epidermal growth factor receptor (EGFR) is commonly expressed in colorectal cancers but not in most normal tissues, raising the possibility that this receptor could serve as a target for highly selective therapy. Based on preclinical studies demonstrating that antagonists of EGFR resulted in the inhibition of tumor growth, the development of clinical reagents has been aggressively pursued. Early clinical studies demonstrated antitumor activity of EGFR inhibitors in patients with advanced colorectal cancer, with acceptable toxicity. This early success fueled rapid clinical development. In this article, we will review the current status of EGFR inhibitors in the treatment of patients with colorectal cancer, in an effort to describe both how far we have come as well as where we need to go in optimizing this promising therapeutic approach.
表皮生长因子受体（EGFR）在结直肠癌中普遍表达，但在大多数正常组织中不表达，这增加了该受体可作为高选择性治疗靶点的可能性。基于临床前研究表明EGFR拮抗剂可抑制肿瘤生长，人们积极开展临床试剂的研发。早期临床研究显示，EGFR抑制剂对晚期结直肠癌患者具有抗肿瘤活性，且毒性可接受。这一早期成功推动了快速的临床发展。在本文中，我们将回顾EGFR抑制剂在结直肠癌患者治疗中的现状，旨在阐述我们在这一有前景的治疗方法优化方面已经取得的进展以及未来的努力方向。
